Female CEOs
Health
Pharmaceutical
Editas Medicine
$25.399876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$25.39
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.60 (2.42%) Today
$0.00 (0.00%) As of 4:05 PM EDT after-hours
Why Robinhood?
You can buy or sell EDIT and other stocks, options, ETFs, and crypto commission-free!
About EDIT
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR); and CRISPR associated protein 9 (Cas9). Read More The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu on September 3, 2013 and is headquartered in Cambridge, MA.
Employees
133
Headquarters
Cambridge, Massachusetts
Founded
2013
Market Cap
1.21B
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
534.45K
High Today
$25.62
Low Today
$24.71
Open Price
$25.01
Volume
593.51K
52 Week High
$35.66
52 Week Low
$17.80
Collections
Female CEOs
Health
Pharmaceutical
Therapy
Medical
Technology
Biotechnology
2016 IPO
Price Paid on Robinhood
10% Lower
Right Now
52 Week Low
$17.80
Average Price Paid
$28.17
52 Week High
$41.43
Analyst Ratings
64%
of 11 ratings
Buy
64%
Hold
36%
Sell
0%
EDIT Earnings
-$0.84
-$0.67
-$0.49
-$0.32
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
—
Actual
Expected Aug 6, After Hours